Cell Therapy Shows Promise in Parkinson’s – MedPage Today
stemadminStem Cell MedicineNo comments

Dopaminergic progenitor cells derived from a Parkinson's disease patient's own skin cells and injected into his putamen showed evidence of survival and were associated with improved motor scores and quality of life measures. The cells were implanted into the 69-year-old Parkinson's patient's putamen in two procedures, left hemisphere followed by right hemisphere, 6 months apart. PET imaging with a dopaminergic activity tracer up to 24 months suggested graft survival, reported Jeffrey Schweitzer, MD, PhD, of Massachusetts General Hospital, and colleagues, in the New England Journal of Medicine.

Read more
Coronavirus: Emirati dentist who received stem cell therapy doing well – Gulf News
stemadminStem Cell MedicineNo comments

Emirati dentist with the officials Image Credit: Supplied Ras Al Khaimah: An Emirati dentist, who received stem cell therapy after she got infected with coronavirus (COVID-19) due to transmission from a patient, was recently visited by Dr Mohamed Salim Al Olama, undersecretary of the Ministry of Health and Prevention (MoHAP) and head of the Board of Directors of the Emirates Health Services Corporation. Dr Muhra Abdul Rahim Al-Awadi, who underwent the innovative stem cell therapy, is one of the current patients at Obaidullah Elderly Hospital in Ras Al Khaimah. Dr Al Olama also made a series of field visits to determine the readiness of various hospitals and the conditions of medical cadres across the country, according to MoHAP

Read more
Magenta Therapeutics Presents Data at Annual Meeting of American Society of Gene and Cell Therapy Demonstrating Cells Mobilized with MGTA-145 in a…
stemadminStem Cell MedicineNo comments

MGTA-145 was shown to be a rapid, reliable, efficient and G-CSF-free method to obtain high numbers of functional HSCs in a Phase 1 trial; the cells could be gene modified and engraft in animals. MGTA-145 could be used to improve collection and gene therapy outcomes Additional preclinical data show MGTA-145 serves as efficient, same-day mobilization regimen for in vivo HSC gene therapy in animals, which could be applicable in treating sickle cell disease and other genetic disorders CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics(Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of blood and immune reset to more patients, presented preclinical data on its stem cell mobilization therapy clinical candidate, MGTA-145, this week at the annual meeting of the American Society of Gene and Cell Therapy (ASGCT).

Read more
UAE’s first Covid-19 patient to recover after stem-cell therapy tells of medical journey – The National
stemadminStem Cell MedicineNo comments

The first UAE patient to recover from Covid-19 after stem-cell therapy has told of his gruelling journey to "full health" after being placed in a coma to stop his organs shutting down. Abdullahi Rodhile, 50, from Somalia, contracted the virus on March 30 and, because of an existing heart condition, his health deteriorated quickly

Read more
Genespire and SR-Tiget announce strategic alliance for the development of transformative gene therapies for genetic diseases and disclose…
stemadminStem Cell MedicineNo comments

Genespire and SR-Tiget announce strategic alliance for the development of transformative gene therapies for genetic diseases and disclose collaboration focus Pre-clinical data from SR-Tiget, included in the alliance with Genespire, to be presented at ASGCT 23rd Annual Meeting Italy, Milan, 13 May 2020: The San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), one of the worlds leading gene therapy research institutes jointly managed by Fondazione Telethon and Ospedale San Raffaele and Genespire, a gene therapy company developing transformative therapies for genetic diseases, and spin-out of SR-Tiget, announced today their alliance on the research and development of candidate therapeutic products for people affected by primary immunodeficiencies and metabolic diseases based on novel gene editing and lentiviral vector technologies developed by SR-Tiget. Genespire was co-founded in March 2020 by SR-Tiget director and gene therapy pioneer Prof

Read more
Surplus antioxidants are pathogenic for hearts and skeletal muscle – The Mix
stemadminStem Cell MedicineNo comments

This discovery may have clinical importance in management of heart failure. This discovery may have clinical importance in management of heart failure.Many heart diseases are linked to oxidative stress, an overabundance of reactive oxygen species. The body reacts to reduce oxidative stress where the redox teeter-totter has gone too far up through production of endogenous antioxidants that reduce the reactive oxygen species

Read more

Theme: Illdy.